Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lymphoma: CLL/SLL

April 10, 2015

Join Jeremy Abramson, MD and Jeffrey Barnes, MD as they present their multidisciplinary expertise on a range of cases pertaining to CLL and SLL.

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are characterized by progressive accumulation of abnormal lymphocytes in the peripheral blood, bone marrow, and lymphoid tissues. Cytogenetic abnormalities are present in the majority of patients with CLL/SLL. The presence of del(13q) as a sole abnormality is associated with a favorable prognosis whereas del (17p) affecting TP53 gene or del (11q) are associated with disease progression and reduced survival. CLL/SLL is diagnosed mainly in older patients, who often present with multiple comorbidities. Since the presence of comorbid conditions is an important prognostic factor, in addition to the disease stage and patient’s age, treatment options should be based on the presence or absence of comorbid conditions. Del (17p) and del (11q) are then used to direct treatment options, for patients with symptomatic disease when indications are present.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for the treatment of patients with CLL/SLL
  • Describe the multidisciplinary aspects of the management of patients with CLL/SLL
  • Identify the key characteristics of CLL/SLL that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
04/09/2015
Course expires: 
06/14/2015
Event starts: 
04/10/2015 - 11:00am
Event ends: 
04/10/2015 - 12:00pm
Cost:
$0.00

Jeremy Abramson, MD
Massachusetts General Hospital Cancer Center

Jeffrey Barnes, MD
Massachusetts General Hospital Cancer Center

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
04/09/2015
Course expires: 
06/14/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing